In their 2020 Global Public Policy Position paper, the USP highlights the growing concern over and risk of counterfeit pharmaceuticals, emphasizing that "poor-quality medicines cause more than one million deaths per year, reduce the effectiveness of authentic medical treatment, waste national resources, and contribute to antimicrobial resistance." (1)
The breadth of the challenge and response to counterfeit pharmaceuticals spans communities, nations, and expertise. Join the AAPS Global Health Community and invited guests on March 21 at 9am PST / 12pm EST for a virtual discussion group focused on this issue and the collaborative and cross-functional approaches that those across the industry and world are taking to drive solutions.
Our invited guests include experts in this area to share their own experiences and thoughts on the problem statement and how we as a community can support these efforts:
- Sister Zita, Medical Missionaries of Mary - Tanzania
- Dr. Chaitanya Koduri, Director of International Government and Regulatory Engagement & Global External Affairs - USP
- Tony Zook, Associate Vice President, Global Security & Head of Global Product Integrity Program - Merck
- Subhash Mandal, Former Pharmaceutical Regulator, Government of West Bengal & current National Honorary General Secretary for the Indian Pharmaceutical Association
Microsoft Teams
Join the meeting Using This Link on March 21, 9am PST
Meeting ID: 291 078 563 078
Passcode: KY2jj6KR
(1) USP Global Public Policy Position: Combatting Substandard and Falsified Medicines (2020).
------------------------------
Erica Schlesinger Ph.D.
VP, Technical Development
Seran Biosciences, LLC
Bend OR
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------